STOCK TITAN

Repligen Corporation - RGEN STOCK NEWS

Welcome to our dedicated page for Repligen Corporation news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen Corporation stock.

Repligen Corporation (NASDAQ: RGEN) is a global life sciences company specializing in the development, production, and commercialization of innovative bioprocessing technologies and systems that enhance the efficiency of biological drug manufacturing. Headquartered in Waltham, Massachusetts, the company operates additional manufacturing facilities in Sweden, Estonia, France, Germany, Ireland, the Netherlands, and the United States.

Repligen is renowned for its high-quality bioprocessing products, which are essential in the production of biological drugs. The company's product portfolio includes Protein A, a critical reagent used in the manufacturing of monoclonal antibody-based therapeutics, and several growth factor products that boost cell culture productivity in biomanufacturing. Additionally, Repligen offers OPUS™ (Open Platform User Specified) single-use chromatography columns, which are pivotal in the biologics purification process.

The company serves a diverse customer base that includes major life sciences and biopharmaceutical companies, as well as contract development and manufacturing organizations (CDMOs) worldwide. Repligen markets its products globally through a direct sales organization in the U.S., Europe, and Asia, complemented by strategic partnerships in select regions. North America remains the primary market, contributing the majority of the company's revenue.

Recent achievements include the acquisition of Metenova AB, a leading innovator in magnetic mixing technologies, to expand its Fluid Management portfolio. Despite challenges in the bioprocessing market, Repligen continues to exhibit resilience with steady revenue growth, particularly in its Analytics and Chromatography franchises.

Financially, Repligen reported second quarter revenues of $159.2 million in 2023 and has adjusted its full-year revenue guidance to a range of $635-$665 million. The company remains optimistic about overcoming current market headwinds, with a growing pipeline of opportunities expected to bolster orders in the fourth quarter.

Overall, Repligen's commitment to bioprocessing technology leadership and continuous innovation positions it as a significant player in the life sciences industry, driving advancements that support the development of life-saving biological drugs.

News
Rhea-AI Summary

Repligen (NASDAQ:RGEN) announced a leadership transition plan where Tony J. Hunt will move from CEO to Executive Chair, and Olivier Loeillot will become President and CEO, effective September 1, 2024. Hunt has been CEO since May 2015, leading the company to significant growth, including an increase in revenue from $63 million in 2014 to $639 million in 2023. Loeillot, who joined Repligen in October 2023, brings nearly 30 years of industry experience, including leadership roles at Cytiva and GE Healthcare Life Sciences. Current Board Chair Karen A. Dawes will become Lead Independent Director.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.85%
Tags
none
-
Rhea-AI Summary

Ecolab, in partnership with Repligen , announced the commercial launch of DurA Cycle Affinity Resin, designed for large-scale purification in biologic manufacturing. This product, launched at BIO 2024 in San Diego, targets efficient monoclonal antibody production, reducing costs for biologic drug developers. The launch reflects Ecolab's ongoing commitment to bioprocessing innovations, following two other resins launched in the past eighteen months. The partnership aims to address complex challenges in biologic manufacturing and is bolstered by Ecolab's investment in a new production facility in Landenberg, PA, complementing its UK-based facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
none
-
Rhea-AI Summary

Repligen (NASDAQ:RGEN) announced its participation in two upcoming June investor conferences.

The company will present at William Blair’s 44th Annual Growth Stock Conference in Chicago from June 4-6, 2024. CEO Tony J. Hunt will give a company overview on June 5 at 12:00 p.m. CT.

Additionally, Repligen will participate in Jefferies’ Global Healthcare Conference in New York from June 5-6, 2024. President and Chief Commercial Officer Olivier Loeillot, and CFO Jason K. Garland, will join an analyst-led discussion on June 6 at 11:30 a.m. ET.

Both presentations will be webcast live and accessible via the company's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
conferences
Rhea-AI Summary

Repligen (NASDAQ:RGEN) will attend several investor conferences in May, including RBC Capital Markets' Global Healthcare Conference in New York, Craig-Hallum's Institutional Investor Conference in Minneapolis, and Leerink Partners' Healthcare Crossroads Conference in Austin. Jason K. Garland, Chief Financial Officer, will participate in analyst-led discussions and one-on-one meetings with investors at each event. Live webcasts of the RBC and Leerink presentations will be accessible via Repligen's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
conferences
-
Rhea-AI Summary

Repligen reported first quarter revenue of $151 million, a 16% increase in new modalities revenue, and a 12% increase in Filtration (non-COVID) revenue year-over-year. The company achieved a nine-month book-to-bill ratio of 1.03. Financial performance in Q1 2024 saw a decline in reported revenue and gross profit compared to Q1 2023, primarily due to COVID-related revenue absence and a decline in Proteins revenue. Adjusted figures showed a decrease in income from operations and net income. Cash, cash equivalents, and short-term investments at the end of Q1 2024 were $780.6 million. Repligen reiterated its financial guidance for full year 2024, expecting orders to pick up in the second half of the year. The company's adjusted financial guidance for FY 2024 remains unchanged, with total reported revenue expected to be in the range of $620M - $650M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
-
Rhea-AI Summary
Repligen (NASDAQ:RGEN) will report its first quarter 2024 financial results on May 1, 2024. A conference call and webcast will be held to discuss business updates and financial results for the reporting period ended March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
conferences earnings
Rhea-AI Summary
Repligen (NASDAQ:RGEN) appoints Maggie A. Pax to its Board of Directors, expanding the board to nine members. Ms. Pax brings over 25 years of experience in leading growth strategies for global companies, including roles at Thermo Fisher Scientific. Repligen's leadership team welcomes her extensive industry expertise, strategic planning skills, and innovation focus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
management
-
Rhea-AI Summary
Repligen Corporation (RGEN) reports fourth quarter revenue of $156 million and full year revenue of $639 million. The company highlights positive momentum in new modalities, closed acquisition of Metenova AB, launched TangenX® SC, and published a Sustainability report. Financially, RGEN's Q4 2023 saw a decrease in total revenue and gross profit compared to 2022, with a loss from operations and net loss. The company's cash position improved to $751.3 million. RGEN provides financial guidance for FY 2024 with expected revenue of $620M - $650M and adjusted net income of $80M - $84M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
-
Rhea-AI Summary
Repligen Corporation (RGEN) will report its fourth quarter 2023 financial results on February 21, 2024. A conference call and webcast will be held to discuss business updates and financial results for the reporting periods. The call will be accessible by dialing toll-free for domestic and international callers, and a webcast will be available via the Investor Relations section of the Company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
conferences earnings
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN) to present at 42nd Annual J.P. Morgan Healthcare conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
conferences

FAQ

What does Repligen Corporation specialize in?

Repligen Corporation specializes in developing, producing, and commercializing innovative bioprocessing technologies and systems for biological drug manufacturing.

Where is Repligen's headquarters located?

Repligen's corporate headquarters are located in Waltham, Massachusetts, USA.

What are some key products offered by Repligen?

Repligen offers Protein A for monoclonal antibody production, growth factors for cell culture productivity, and OPUS™ single-use chromatography columns for biologics purification.

Who are Repligen's primary customers?

Repligen's primary customers include major life sciences and biopharmaceutical companies, as well as contract development and manufacturing organizations (CDMOs) worldwide.

How does Repligen market its products?

Repligen markets its products globally through a direct sales organization in the U.S., Europe, and Asia, along with strategic partners in select regions.

What recent acquisition has Repligen made?

Repligen recently acquired Metenova AB, a leader in magnetic mixing technologies, to enhance its Fluid Management portfolio.

What was Repligen's revenue for the second quarter of 2023?

Repligen reported second quarter revenues of $159.2 million in 2023.

What is Repligen's revenue guidance for the year 2023?

Repligen has adjusted its full-year revenue guidance to range between $635-$665 million for 2023.

Which regions contribute the most to Repligen's revenue?

North America is the primary market, contributing the majority of Repligen's revenue.

What is Repligen's focus area?

Repligen focuses on Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins to support biopharmaceutical drug developers and CDMOs.

Repligen Corporation

Nasdaq:RGEN

RGEN Rankings

RGEN Stock Data

7.04B
55.88M
6.57%
102.36%
7.6%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
WALTHAM